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Gene Regulation by 1,25-Dihydroxyvitamin D3
in CD4þCD25þ Cells Is Enabled by IL-2
Shelley Gorman1, Melinda A. Judge1 and Prue H. Hart1
Vitamin D may be responsible for reducing the development and severity of autoimmune and allergic diseases.
Topically applied 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) enhances the immunoregulatory ability of
CD4þCD25þ T cells residing in the skin-draining lymph nodes (SDLNs) of mice. The mechanisms responsible
were investigated by examining the expression of 84 cytokine and cytokine-related genes in a 96-well gene array.
CD4þCD25þ cells isolated from the SDLNs of BALB/c mice, 24 and 96hours after topical treatment with
1,25(OH)2D3, consistently expressed increased IL-2 mRNA levels and also secreted enhanced quantities of IL-2
after ex vivo stimulation with phorbol 12-myristate 13-acetate and ionomycin. CD4þCD25þ cells from the
lymph nodes of naive mice constitutively express the vitamin D receptor, allowing direct modulation by
1,25(OH)2D3. However, in vitro treatment with 1,25(OH)2D3 did not modify the expression of 84 tested cytokine
and cytokine-related mRNAs. It was only in the presence of IL-2 that 1,25(OH)2D3 increased the expression of
genes including IL-2 and TLR4. Further, 1,25(OH)2D3 enhanced the ability of IL-2 to stimulate CD4þCD25þ cells
to proliferate in vitro and also regulate contact hypersensitivity responses on adoptive transfer into naive mice.
Therefore, 1,25(OH)2D3 enabled by IL-2 can directly enhance the regulatory potential of CD4þCD25þ T cells to
control immune disease.
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INTRODUCTION
With sunlight-derived UVB (290–315nm) exposure, 7-dehy-
drocholesterol in skin is converted into pre-vitamin D3. This
molecule then isomerizes with body heat into vitamin D3.
Vitamin D binding protein transports much of the vitamin D3
to the liver and kidneys for further hydroxylation into the
active hormone, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3).
Skin cells can synthesize local concentrations of 2–5 nM
1,25(OH)2D3 after UVB irradiation (Lehmann et al, 2003;
Bikle et al, 2004; Gupta et al, 2007). However, with reduced
sunlight exposure resulting from our increasingly indoor
lifestyle and the difficulties associated with oral vitamin D
supplementation, vitamin D insufficiency is an emerging
problem in many countries, including ‘‘sun-drenched’’
Australia (van der Mei et al, 2007).
Vitamin D deficiency may increase the risk of acquiring
autoimmune and allergic disease (Litonjua and Weiss, 2007;
Cantorna et al, 2008). Psoriasis (and similar skin diseases) can
be treated through topical application of 1,25(OH)2D3 (or
synthetic analogs) (Sigmon et al, 2009). 1,25(OH)2D3 reduces
morbidity in the skin through direct effects on keratinocyte
proliferation and differentiation in psoriatic lesions (reviewed
by Sigmon et al (2009)) and also through immunoregulation.
1,25(OH)2D3 produced in UVB-irradiated skin may con-
tribute to the systemic immunomodulatory effects of UV
irradiation (reviewed by Loser and Beissert (2009)). Indeed,
1,25(OH)2D3 can modulate the function of immune cells
located in the skin and underlying lymphatic tissue including
Langerhans cells (Fujita et al, 2007), mast cells (Shalita-
Chesner et al, 1998; Baroni et al, 2007), and regulatory
T cells (Gorman et al, 2007a; Ghoreishi et al, 2009).
We previously identified that topical 1,25(OH)2D3 treat-
ment or UVB irradiation of the skin of naive BALB/c mice
increased the suppressive capacity of CD4þCD25þ T cells
(490% Foxp3þ ) in the draining lymph nodes (DLNs;
Gorman et al, 2007a). However, in the absence of any
further antigenic stimulation, there was no change in the
number of these cells in the DLNs after topical treatment
with 1,25(OH)2D3. These results suggested that UVB-induced
1,25(OH)2D3 production in skin affects downstream
immune responses by increasing the suppressive activity
of CD4þCD25þ cells isolated from DLNs. In this study,
we focused on determining how topical application of
1,25(OH)2D3 increased the suppressive activity of CD4þ
CD25þ cells and began by examining the differential
expression of mRNAs in these cells after skin treatment.
Surprisingly, after topical treatment with 1,25(OH)2D3, the
expression of IL-2 mRNA and protein by CD4þCD25þ
cells isolated from the skin DLNs (SDLNs) was increased.
Further in vitro analysis revealed that 1,25(OH)2D3
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synergizes with IL-2 to promote the regulatory activity of
CD4þCD25þ cells.
RESULTS
CD4þCD25þ cells from mice treated with topical
1,25(OH)2D3 secreted increased levels of IL-2
mRNA was extracted from CD4þCD25þ cells, purified
from the SDLNs 24 or 96 hours after topical 1,25(OH)2D3
(125 ng) or vehicle treatment. Using a PCR array system
(SABiosciences, Frederick, MD), we assessed the expression
of 84 different genes in three experiments. At 24 hours after
topical 1,25(OH)2D3 treatment, there was a significant
upregulation in 6 of the 84 mRNAs, including IL-2, CCL7,
and Toll-like receptor 4 (TLR4) (Figure 1a). At 96 hours after
topical 1,25(OH)2D3 treatment, there was a significant
upregulation in only IL-2 and CCL7 mRNAs (Figure 1b).
The expression of the other mRNAs tested, including CD4
and the immunoregulatory molecules CTLA4 and IL-10, were
not significantly modified by 1,25(OH)2D3 (Figure 1a and b,
Supplementary Table S1 online). Using an in-house real-time
PCR system, we confirmed that IL-2 and not IL-10 mRNA was
upregulated at least 2-fold in CD4þCD25þ cells 96 hours
after topical 1,25(OH)2D3 application (Figure 1c). TGFb and
Foxp3 mRNA levels were also not modified in
CD4þCD25þ cells isolated 24 or 96 hours after topical
1,25(OH)2D3 application (Figure 1c for 96 hours, data not
shown for 24 hours).
IL-2 protein secretion by CD4þCD25þ cells from
1,25(OH)2D3-treated mice was investigated because IL-2 is a
target of 1,25(OH)2D3 in the immune system, and has been
shown to be required for the suppression by 1,25(OH)2D3 of
colitis in mice (Bemiss et al, 2002). CD4þCD25± cells were
purified from the SDLNs of mice treated topically 96hours
earlier with 1,25(OH)2D3 or vehicle. The purity and expression
of CD25 on CD4þCD25þ cells isolated from the SDLNs of
vehicle- or 1,25(OH)2D3-treated mice were equivalent (Fig-
ure 2). These cells were then cultured for 18 hours with either
(i) plate-bound anti-CD3 mAb, (ii) plate-bound anti-CD3 mAb
with soluble anti-CD28 mAb, or (iii) phorbol 12-myristate 13-
acetate (PMA) and ionomycin. IL-2 concentrations detected in
culture supernatants of CD4þCD25þ cells stimulated with
plate-bound anti-CD3 mAb with or without anti-CD28 mAb
were not significantly greater than nonstimulated controls
(data not shown). However, with PMA and ionomycin
treatment, significant IL-2 levels were detected in cell super-
natants (Figure 2c). CD4þCD25þ cells from the SDLNs of
mice treated topically with 1,25(OH)2D3 secreted 2-fold more
IL-2 than those from vehicle-treated mice (Figure 2c).
CD4þCD25 cells secreted approximately 10-fold more IL-
2 than CD4þCD25þ cells stimulated with PMA and
ionomycin (data not shown). There was no difference in IL-
10 protein levels in the same supernatants of CD4þCD25þ
or CD4þCD25 cells from vehicle- or 1,25(OH)2D3-treated
mice (data not shown).
In previous studies, there was no difference in the
expression of the T-cell activation/memory/mucosal cell
molecules, CD44, CD54, CD69, CD62L, CD45RB, and
CD103 on CD4þCD25± cells isolated from the SDLNs of
1,25(OH)2D3- or vehicle-treated mice, suggesting that
CD4þ cells were not activated by topical 1,25(OH)2D3
treatment (Gorman et al, 2007a). We also observed no
difference in the expression of regulatory cell markers Foxp3,
CTLA-4, or CD39 on CD4þCD25þ cells in the SDLNs 4
days after topical 1,25(OH)2D3 treatment (Gorman et al.,
2007a, data not shown). However, the increased IL-2
secretion into supernatants by CD4þCD25þ cells from
1,25(OH)2D3-treated mice might have been due to co-
isolated CD4þCD25þ Foxp3 effector (nonregulatory)
cells. More than 90% of the original CD4þCD25þ cells
expressed Foxp3 (Figure 2d, nonstimulated). An IL-2 secre-
tion assay (Miltenyi Biotec, Bergisch Gladbach, Germany)
was used to identify the IL-2-secreting cells within the
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Figure 1. IL-2 mRNA levels are increased in CD4þCD25þ cells from
the skin-draining lymph nodes of mice topically treated with 1,25-
dihydroxyvitamin D3. The expression of 84 mRNAs in CD4þCD25þ
cells from the SDLNs of BALB/c mice treated topically 24 (a) or 96 (b) hours
earlier with vehicle or 125 ng 1,25(OH)2D3 (vitD) was assessed using the
Th1-Th2-Th3 RT2 profiler PCR with results for nine genes shown (see also
Supplementary Table S1 online) as their expression was either (i) upregulated
after topical 1,25(OH)2D3 treatment or (ii) previously associated with
regulatory T-cell function. In (c), fold increase in mRNA for IL-2, IL-10, TGFb,
and Foxp3 in CD4þCD25þ cells 96 hours after topical 1,25(OH)2D3
treatment was detected using in-house real-time PCR assays. Results are
for three independent experiments (meanþ SEM, *Po0.05).
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CD4þCD25þ cells purified from the SDLNs of
1,25(OH)2D3- or vehicle-treated mice, with intracellular
expression of Foxp3 also measured. With PMA and ionomy-
cin, both Foxp3þ and Foxp3 cells were identified as IL-2-
secreting cells (Figure 2d) with relatively more Foxp3þ IL-2-
secreting cells. The proportion of IL-2-secreting cells was not
modified by prior in vivo treatment with 1,25(OH)2D3
(vehicle¼ 21.4±0.2, 1,25(OH)2D3¼21.1±1.7, mean±-
SEM, n¼ 3 replicates). In contrast, nearly all PMA and
ionomycin-stimulated CD4þCD25 cells were identified as
IL-2-secreting cells (495% cells), with the mean fluores-
cence intensity of IL-2 on CD4þCD25 cells 10-fold greater
than that observed on CD4þCD25þ cells (data not shown).
It is possible that a small fraction of highly IL-2-secreting
‘‘nonregulatory’’ T cells could account for increased IL-2
production by purified CD4þCD25þ cells from
1,25(OH)2D3-treated mice. An alternative assay of IL-2
production using an inhibitor of protein secretion that
allowed IL-2 accumulation in the cells gave similar results.
Direct effects of 1,25(OH)2D3 on the expression of 84 mRNAs
expressed in CD4þCD25± cells
The effects of 1,25(OH)2D3 on gene expression during the
activation of CD4þ T cells have been previously assessed
(Mahon et al, 2003). However, the direct effects of
1,25(OH)2D3 in vitro on isolated CD4þCD25± T cells are
unknown. CD4þCD25± cells from the lymph nodes of
naive BALB/c mice were incubated with either 10 nM
1,25(OH)2D3 or the equivalent amount of diluent used to
dissolve the 1,25(OH)2D3 (ethanol). After 4 hours the expres-
sion of 84 cytokine-related genes was determined with fold-
change (mean±SEM, n¼ 3 experiments) of mRNA levels
detailed in Supplementary Table S3 online. The 4 hours time
was initially selected because we were interested in the direct
effects of 1,25(OH)2D3 upon primary transcript expression.
After 4 hours the only mRNA to be significantly modified in
CD4þCD25þ cells by 1,25(OH)2D3 was IL-6 (Figure 3a,
Supplementary Table S2 online). The expression of none of
the tested mRNAs was significantly altered by 1,25(OH)2D3
treatment of CD4þCD25 cells (Supplementary Table S2
online).
CD4þCD25þ T cells constitutively express the vitamin D
receptor
As the expression of only 1 of 84 genes was regulated after
in vitro 1,25(OH)2D3 treatment, the expression of vitamin D
receptor (VDR) protein was measured in CD4þCD25þ cells
to confirm that these cells can respond to 1,25(OH)2D3
stimulation. Intracellular expression of the VDR in lymph
node cells from naive BALB/c mice was examined by flow
cytometry using the appropriate isotype controls as pre-
viously shown (Meindl et al, 2005). Both CD4þCD25þ
(Figure 4a) and CD4þCD25 (Figure 4b) cells expressed the
VDR intracellularly. The constitutive expression of the VDR
indicates that the CD4þCD25þ and CD4þCD25 cells
could both be regulated directly by 1,25(OH)2D3.
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Figure 2. IL-2 protein levels are enhanced in supernatants of stimulated CD4þCD25þ cells from mice topically treated with 1,25-dihydroxyvitamin D3
(1,25(OH)2D3). CD4þCD25þ cells were purified from the skin-draining lymph nodes (SDLNs) of BALB/c mice treated topically 96 hours earlier with vehicle
or 125 ng 1,25(OH)2D3 (vitD). In (a), the live CD3þCD4þ cells that express (b) CD25 are shown. In (c) and (d), cells were stimulated (2.5 105 per well of
1ml) for 18 hours with phorbol 12-myristate 13-acetate (PMA; 10 mgml1) and ionomycin (400 ngml1). As a negative control, CD4þCD25þ cells from
vehicle-treated mice were cultured without further stimulation (nonstimulated). In (c), IL-2 levels in supernatants are shown as meanþ SEM (n¼ 3 wells per
treatment, *Po0.05). In (d), the intracellular expression of Foxp3 and the proportions of IL-2-secreting cells for representative cultures are shown.
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1,25(OH)2D3 in the presence of IL-2 increased the expression of
IL-2 and TLR4 mRNAs by CD4þCD25þ cells
We hypothesized that the lack of effect of 1,25(OH)2D3 on
CD4þCD25± cell gene expression in vitro may have been
due to the absence of a costimulatory factor such as IL-2. In
addition, due to the expression of the IL-2R, IL-2 can
modulate the regulatory function of CD4þCD25þ cells
(Bensinger et al, 2004). To determine whether IL-2 ‘‘enabled’’
1,25(OH)2D3 to alter the expression of 84 cytokine-related
genes, we first cultured CD4þCD25± cells from the lymph
nodes of naive BALB/c mice with or without IL-2 (6 ngml1)
for 4 hours to examine the effects that IL-2 treatment alone
may have on the expression of the 84 cytokine-related
mRNAs tested above, with fold-change (mean±SEM, n¼3
experiments) of the gene transcripts shown in Supplementary
Table S3 online. A number of transcripts were significantly
regulated by IL-2 in CD4þCD25þ cells (Figure 3b,
Supplementary Table S3 online). IL-2 in vitro did not
significantly alter the expression of any of the 84 mRNAs
tested in the CD4þCD25 cells (Supplementary Table S3
online). Thus, IL-2 can directly affect the expression of
cytokine-related genes in CD4þCD25þ cells.
CD4þCD25± cells were then cultured with and without
1,25(OH)2D3 in the presence of IL-2 (6 ngml
1) and gene
expression examined after 4 hours with fold-change (mean±
SEM, n¼3 experiments) of the gene transcripts shown in
Supplementary Table S4 online. After 4 hours incubation with
IL-2 in vitro, 1,25(OH)2D3 significantly upregulated the
expression of two mRNAs in CD4þCD25þ cells (IL-2 and
TLR4, Figure 3c, Supplementary Table S4 online) and no
mRNAs in CD4þCD25 cells (Supplementary Table S4
online). These were two of the mRNAs that were upregulated
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Figure 3. Fold change in mRNA expression of 12 genes in CD4þCD25þ cells cultured with 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). CD4þCD25þ
cells were purified from the lymph nodes of naive BALB/c mice and cultured for 4 hours with or without 10 nM 1,25(OH)2D3 (a), with and without IL-2
(6 ngml1) (b), or with or without 10 nM 1,25(OH)2D3 in the presence of IL-2 (6 ngml
1) (c). The expression of 84 mRNAs was assessed with results for
12 genes shown (see also Supplementary Tables S2, S3, and S4 online). Results are shown as meanþ SEM (*Po0.05) for three independent experiments,
with fold change relative to the vehicle-treated or untreated cells. Samples were classified as not detected (ND) when the Ct values for both treatments
were X35 cycles in any of the experiments.
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in CD4þCD25þ cells after in vivo topical treatment
with 1,25(OH)2D3 (Figure 1). It is therefore possible that
the expression of these two mRNAs contribute toward the
suppressive activity of CD4þCD25þ cells both after in vitro
treatment with 1,25(OH)2D3 (with IL-2), and topical treat-
ment with 1,25(OH)2D3. These data also suggest that topical
1,25(OH)2D3 application may directly augment the suppres-
sive activity of CD4þCD25þ regulatory cells in the SDLNs,
when cofactors such as IL-2 are available.
1,25(OH)2D3 enhances the proliferation but not skin-associated
migration of CD4þCD25þ cells after in vitro incubation
with IL-2
A potential mechanism for the increased suppressive ability
of CD4þCD25þ cells after topical 1,25(OH)2D3 treatment
could be due to their increased ability to proliferate upon
subsequent exposure to antigen (Gorman et al, 2007a). IL-2 is
known to support the proliferation of T cells, and is often used
to expand human regulatory T cells in vitro (Brusko et al,
2008). In addition, 1,25(OH)2D3 acts with IL-2 to promote
the expression of Foxp3 and CTLA-4 on human
CD4þCD25 cells stimulated for 5 days with anti-CD3-
and anti-CD28-coated beads (Jeffery et al, 2009). To
determine whether 1,25(OH)2D3 affects the ability of IL-2
to expand CD4þCD25þ cells, we isolated CD4þCD25þ
cells from the lymph nodes of naive mice and incubated
them for 96 hours with and without 1,25(OH)2D3 in the
presence or absence of IL-2 in two separate experiments.
CD4þCD25þ cells cultured with IL-2 proliferated to a
much greater extent than those cultured without IL-2
(Figure 5a). In addition, 1,25(OH)2D3 significantly increased
the capacity of IL-2-treated CD4þCD25þ cells to prolifer-
ate byB35%, although 1,25(OH)2D3 treatment alone had no
effect. Therefore, 1,25(OH)2D3 increases the capacity of IL-2
to induce the proliferation and expansion of CD4þCD25þ
cells in vitro.
CD4þCD25þ cells from the SDLNs of vehicle- or
1,25(OH)2D3-treated mice have an equivalent propensity to
migrate to the SDLNs (Gorman et al, 2010). There was also
no change in skin-homing receptor CCR10 mRNA levels in
CD4þCD25þ cells with any 1,25(OH)2D3 treatment
(see Supplementary Tables S1, S3, and S4 online). Further,
CD4þCD25þ cells cultured for 24 hours with or without
1,25(OH)2D3 in the presence or absence of IL-2 had a
similar ability to migrate to the SDLNs (Figure 5b) or other
peripheral lymph node sites (data not shown). The treated
CD4þCD25þ cells (105) from DO11.10 (OVA-TCRþ )
transgenic mice were adoptively transferred into naive
BALB/c mice, which were topically sensitized 24 hours later
with 25 ml 0.5% 2,4-dinitrofluorobenzene (Gorman et al,
2007a). There was no difference in the proportions of
transferred cells (CD4þ OVA-TCRþ Foxp3þ ) in the SDLNs
of recipient mice, 4 days after transfer (Figure 5b). Together,
these data suggest that 1,25(OH)2D3 (with IL-2) does not
modify the ability of CD4þCD25þ cells to migrate into the
SDLNs and other lymphoid sites.
1,25(OH)2D3 enhanced the in vivo suppressive capacity of
CD4þCD25þ cells after in vitro incubation with IL-2
Our investigations suggested that the immunomodulatory
effects of 1,25(OH)2D3 on CD4þCD25þ cells were
dependent on the presence of IL-2. The ability of these cells
to modify in vivo immune responses was investigated as
1,25(OH)2D3 with IL-2 enhances the proliferation and IL-2
production by CD4þCD25þ cells in vitro, both of which
may confound the interpretation of traditional in vitro
proliferation assays. The CD4þCD25þ cells were cultured
for 4 or 24 hours with or without 1,25(OH)2D3 (10 nM) in the
presence of IL-2 (6 ngml1). CD4þCD25þ cells were then
adoptively transferred into naive BALB/c mice. A group of
mice received saline only to control for the effects of the
CD4þCD25þ cell transfer. The suppressive ability of the
CD4þCD25þ cells was assessed using a contact hypersen-
sitivity (CHS) assay; recipient mice were sensitized with 25 ml
of 0.5% 2,4-dinitrofluorobenzene on the shaved ventral
surface 24 hours after the adoptive transfer. To elicit an ear
swelling response, we applied 10 ml of 0.2% 2,4-dinitrofluor-
obenzene to each ear pinnae. There was very similar ear
swelling in mice injected with saline or CD4þCD25þ cells
treated with IL-2 alone (Figure 5c). In contrast,
CD4þCD25þ cells incubated with 1,25(OH)2D3 and IL-2
for 24 hours significantly suppressed CHS responses
(Figure 5c). Ear swelling was reduced by an average of 30%
by CD4þCD25þ cells treated in vitro with 1,25(OH)2D3
and IL-2. This reduction was similar to that previously
reported for increased suppressive ability of CD4þCD25þ
cells isolated from the SDLNs of mice treated with topical
1,25(OH)2D3 (Gorman et al, 2007a). A nonsignificant
suppression (B25%) of ear swelling was observed for cells
cultured with 1,25(OH)2D3 and IL-2 for only 4 hours before
adoptive transfer (data not shown). The extent of suppression
after 24 hours treatment with 1,25(OH)2D3 and IL-2 was
similar to that measured when CD4þCD25þ cells were
incubated with a much higher dose of IL-2 (15 ngml1) for
24 hours before adoptive transfer (Figure 5d). Therefore, in
the presence of IL-2, 1,25(OH)2D3 can increase the
suppressive capacity of CD4þCD25þ cells.
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Figure 4. CD4þCD25þ and CD4þCD25 T cells express the vitamin D
receptor (VDR) intracellularly. Intracellular VDR expression in
CD4þCD25þ and CD4þCD25 cells from the lymph nodes of naive
8-week-old female BALB/c mice was examined by flow cytometry using
CD3, CD4, and CD25 mAb to delineate the two T-cell populations.
CD4þCD25þ (a) and CD4þCD25 (b) cells stained with the VDR mAb
(unshaded) are shown with isotype controls (shaded).
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Discussion
Topically applied 1,25(OH)2D3 increases the suppressive
capacity of CD4þCD25þ cells residing in the SDLNs of
naive mice. This effect is maximal 96 hours after topical
treatment, and although the suppressive activity of these cells
is increased, the numbers of these cells in the SDLNs do not
change (Gorman et al, 2007a). In this study, topical treatment
with 1,25(OH)2D3 enhanced the ability of CD4þCD25þ
cells purified from the SDLNs to express IL-2. As it was also
unclear as to whether co-isolated CD4þCD25þ effector
cells were expressing increased levels of IL-2 mRNA and/or
protein, mechanistic studies were performed with exogenous
IL-2 (6 ngml1) added to CD4þCD25þ cells cultured with
1,25(OH)2D3 to mimic the effects of endogenously derived
IL-2 on CD4þCD25þ cell phenotype and function. In the
presence of IL-2, 1,25(OH)2D3 increased the expression of
IL-2 and TLR4 mRNA in CD4þCD25þ cells, which were
also upregulated in SDLN-derived CD4þCD25þ cells,
after topical 1,25(OH)2D3 application (Figures 1 and 3c).
Together, these data suggest that skin-applied 1,25(OH)2D3
may have direct effects on CD4þCD25þ cells present in
the SDLNs, where IL-2 present in the lymph node micro-
environment may enable topical 1,25(OH)2D3 to affect the
regulatory ability of CD4þCD25þ cells.
Our data suggest that a mechanism by which
1,25(OH)2D3 with IL-2 can directly increase the suppressive
activity of CD4þCD25þ cells is by increasing their
potential to proliferate. In our previous studies, topical
1,25(OH)2D3 application augmented the ability of
CD4þCD25þ cells to proliferate when subsequently
exposed to antigen (Gorman et al, 2007a). 1,25(OH)2D3
further increased the capacity of IL-2 to expand cultured
CD4þCD25þ cells by B35% (Figure 5a). This was
mimicked by a similar increase (B30%) in the ability of
CD4þCD25þ cells to suppress CHS responses after
treatment with 1,25(OH)2D3 and IL-2. These results are
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Figure 5. 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) in the presence of IL-2 enhances the ability of CD4þCD25þ cells to proliferate in vitro and suppress
immune responses in vivo. In these experiments CD4þCD25þ cells were isolated from the lymph nodes of naive BALB/c (a, c, and d) or DO11.10
(b) mice. In (a) and (b), CD4þCD25þ cells were cultured for 96 (a) or 24 (b) hours with or without 10 nM 1,25(OH)2D3 in the presence or absence of IL-2
(6 ngml1). In (a), [H3]-thymidine was added for the last 24 hours of the 96-hour culture period (meanþ SEM, n¼ 3 wells per treatment, *Po0.05, for one
representative experiment). In (b), CD4þCD25þ cells (105) from the lymph nodes of DO11.10 mice were cultured as shown for 24 hours, and were adoptively
transferred into naive BALB/c mice, which were sensitized on the shaved ventral surface 24 hours later with 25 ml of 0.5% 2,4-dinitrofluorobenzene (DNFB;
results are shown as mean±SEM, n¼ 3 mice per treatment). The number of transferred cells (CD4þOVA-TCRþ Foxp3þ ) was determined 3 days after
sensitization. In (c), CD4þCD25þ cells were cultured for 24 hours with or without 10 nM 1,25(OH)2D3 in presence of IL-2 (6 ngml1). In (d), CD4þCD25þ
cells were cultured for 24 hours with or without 15 ngml1 IL-2. In (c) and (d) after culture, CD4þCD25þ cells (2.5105) or 0.9% saline (200 ml) were
adoptively transferred into naive BALB/c mice, which were sensitized 24 hours later with 25ml of 0.5% DNFB, with ears challenged with 10 ml of 0.2% DNFB
per ear pinnae 5 days later (results are shown as mean±SEM, n¼5 mice per treatment, *Po0.05 for all time points).
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reminiscent of similar experiments where 1,25(OH)2D3
induced IL-10 production by human peripheral blood
mononuclear cells, and IL-10 also acted with 1,25(OH)2D3
as a positive autocrine factor for further IL-10 production
(Correale et al, 2009). We did not observe any differences in
the ability of 1,25(OH)2D3 to modulate CD4þCD25þ cell
migration (Figure 5b, Gorman et al, 2007a, 2010) or skin-
chemokine receptor expression (CCR10, Supplementary
Tables S1, S3, and S4 online) after in vitro treatment with
IL-2, or when cells were isolated from topically treated mice.
In contrast, Sigmundsdottir et al. (2007) observed increased
CCR10 expression by 1,25(OH)2D3-treated human T cells,
which were simultaneously activated in vitro through
the TCR.
With topical 1,25(OH)2D3 treatment, there was no
regulation of Foxp3 nor CTLA-4 mRNA or protein expression
in CD4þCD25þ cells. In addition, the level of Foxp3 per
cell (protein or mRNA) was not modified after the treatment
of CD4þCD25þ cells with 1,25(OH)2D3 and IL-2 in vitro
(data not shown), suggesting that Foxp3 (or CTLA-4)
expression per se is not involved in increasing the regulatory
potential of CD4þCD25þ cells after 1,25(OH)2D3 treat-
ment. Others have observed an increase in the number of
Foxp3þ cells and CTLA-4 expression by T cells in the SDLNs
of C57Bl/6 mice treated topically with the 1,25(OH)2D3-
analog calcipotriol, 4 days after further epicutaneous
sensitization with ovalbumin (OVA) (Ghoreishi et al, 2009).
Similarly, Jeffery et al. (2009) found that with TCR
engagement in vitro, the expression of Foxp3 and CTLA-4
protein correlated with increased regulatory activity of
CD4þCD25 cells stimulated with 1,25(OH)2D3 and IL-2.
We propose that in the absence of stimulation through the
TCR, topical treatment with 1,25(OH)2D3 increases the
regulatory activity of stimulated CD4þCD25þ cells without
affecting Foxp3 or CTLA-4 expression, whereas further
antigenic stimulation (which enhances IL-2 production) will
promote the expansion of Foxp3þ cells.
The increased proliferation by CD4þCD25þ cells may
provide only a partial explanation for the enhanced
suppressive ability of these cells after treatment with
1,25(OH)2D3 and IL-2. Another potential mechanism of
action could be through enhanced expression of TLR4 as
observed on cells both after topical 1,25(OH)2D3 or in vitro
treatments with 1,25(OH)2D3 and IL-2. There is some
controversy in the literature as to whether ligation of TLR4
in vitro affects the suppressive function of CD4þCD25þ
T cells (reviewed by Dai et al (2007)). However, in a recent
study, chronic triggering of TLR4 through induced transgenic
expression of the heat shock protein gp96 increased the
regulatory activity of purified CD4þCD25þ cells (Dai et al,
2007).
CD4þCD25þ Foxp3þ cells are not efficient producers
of IL-2 (Thornton and Shevach, 1998). In particular, Su et al.
(2004) showed that the failure of chromatin to remodel at
the proximal promoter region of the IL-2 gene after the
stimulation of CD4þCD25þ cells was responsible for the
poor production of IL-2 by these cells. In our studies, relative
to the CD4þCD25 cells, with both physiological (anti-
CD3 and anti-CD28 mAb) and nonphysiological stimulation
(PMA and ionomycin), the CD4þCD25þ cells secreted
B10-fold less IL-2 (data not shown). However, with in vitro
stimulation with PMA and ionomycin, CD4þCD25þ cells
from mice treated with topical 1,25(OH)2D3 secreted
significantly more IL-2 and cells purified directly from mice
expressed increased levels of IL-2 mRNA. Further,
CD4þCD25þ cells treated with both 1,25(OH)2D3 and
IL-2 also expressed more IL-2 mRNA. Together these data
indicate that 1,25(OH)2D3 can stimulate increased IL-2
production by at least a subset of CD4þCD25þ cells.
At initial glance, our findings with CD4þCD25þ cells
may appear contrary to earlier reports. 1,25(OH)2D3 treat-
ment in vitro inhibited IL-2 production by T cells through
transcriptional repression of the IL-2 gene (Alroy et al, 1995)
and reduced the production of IL-2 by, and the proliferation
of, mitogen-stimulated CD4þ T-helper cells (Lemire et al,
1985; Boonstra et al, 2001; Mahon et al, 2003). A major
difference between our findings and those published are that
previous observations were from studies using unfractionated
T-cell populations. When we examined IL-2 production by
CD4þCD25 cells after PMA and ionomycin stimulation,
cells from the SDLNs of mice treated topically with
1,25(OH)2D3 secreted significantly less IL-2 than those from
vehicle-treated mice (vehicle¼2,900±200; 1,25(OH)2D3¼
2,300±70 pgml1, mean±SEM, n¼ 3 replicates). These
observations indicate that subpopulations within a larger
unfractionated cell population may respond differently to
1,25(OH)2D3. Alternatively, the ability of 1,25(OH)2D3 to
suppress T-cell proliferation may be due to the emergence of
Foxp3þ cells within the stimulated T cells (Jeffery et al,
2009). A microarray-based study of CD4þ T cells exposed to
1,25(OH)2D3 during activation with PMA and ionomycin
identified many gene targets of 1,25(OH)2D3, which varied
depending on the differentiation and activation status of the
CD4þ T cells (Mahon et al, 2003). This highlights how
changes to cell culture conditions can greatly modify
outcomes observed in vitro. In our studies, we examined
the effects of 1,25(OH)2D3 on purified subpopulations of
CD4þ T cells stimulated for only a short time in vitro
without further antigenic stimulation. Further, only 10 nM
1,25(OH)2D3 was used, which is less than the concentration
used by others (Jeffery et al, 2009). Our observations are
supported by studies of IL-2 knockout mice, where IL-2 is a
target of 1,25(OH)2D3 in the immune system, and may be
required for the suppression of colitis in mice (Bemiss et al.,
2002).
These results highlight the potential impact that
1,25(OH)2D3 in the skin has on immune cells, in particular
regulatory T cells, and how vitamin D deficiency may
compromise the ability of these cells to control immune
responses that occur during autoimmune disease and allergy.
The ability of topical 1,25(OH)2D3 (or analogs) to modify
immune responses has been shown in both mice (Guo et al,
1992; Ghoreishi et al, 2009) and humans (Hanneman et al,
2006; Damian et al, 2009), where this treatment suppressed
CHS responses. Our ongoing studies aim to identify a
mechanism by which topical 1,25(OH)2D3 application may
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be effective in treating inflammatory skin conditions such as
psoriasis, and other allergic diseases including asthma, where
subcutaneous immunotherapies incorporating 1,25(OH)2D3
reduce respiratory inflammation during allergic airway
disease (Taher et al, 2008). Due to the apparent prevalence
of vitamin D insufficiency, it is important for us to continue to
investigate the immunomodulatory effects of vitamin D both
in the skin and in associated lymphatic tissue.
MATERIALS AND METHODS
Mice
Female 8-week-old BALB/c mice were purchased from the Animal
Resources Centre (Murdoch, Western Australia). Mice transgenic for
the OVA323–339 (ISQAVHAAHAEINEAGR)-specific T-cell receptor-
ab (DO11.10) on a BALB/c background were originally purchased
from the Jackson Laboratory (Bar Harbor, ME) and bred in-house. All
experiments were performed according to the ethical guidelines of
the National Health and Medical Research Council of Australia and
with approval from the Telethon Institute for Child Health Research
Animal Ethics Committee.
Vitamin D application
A 100 ml aliquot containing 125 ng 1,25(OH)2D3 (Sigma Chemical
Company, St Louis, MO) diluted in ethanol, propylene glycol, and
water mixed at a 2:1:1 ratio was painted onto a clean-shaven 8 cm2
dorsal skin surface of mice as described previously (Gorman et al,
2007a).
Purification of CD4þCD25þ cells
At 24 or 96 hours after topical skin treatment, CD4þCD25þ or
CD4þCD25 cells (X95% pure, as determined by flow cytometry)
were isolated from the SDLNs (inguinal, axillary, and brachial) of
vehicle- or 1,25(OH)2D3-treated mice or lymph nodes (inguinal,
axillary, brachial, mesenteric, auricular, and para-aortic) of naive
BALB/c mice using the CD4þCD25þ regulatory T-cell isolation kit
(Miltenyi Biotec) and the AutoMACS cell separator (Miltenyi Biotec).
More than 90% of CD4þCD25þ cells from the lymph nodes of
naive, vehicle- or 1,25(OH)2D3-treated BALB/c mice express the
regulatory cell marker Foxp3 intracellularly (Gorman et al, 2007a).
Measuring mRNA in CD4þCD25± cells (PCR arrays)
RNA was purified from cells, cDNA transcribed, and real-time PCR
performed as described previously (Gorman et al, 2010), using Th1-
Th2-Th3 RT2 profiler PCR arrays (PAM034A, 96-wells; SABios-
ciences). Fold-change was determined by using the 2DDCt method
specified by the manufacturer. Samples were classified as not
detected (ND) by this system when the Ct values for the expression of
genes for both treatments were X35 cycles in any of the repeated
experiments.
Measuring mRNA in CD4þCD25± cells (in-house primers)
The expression of IL-2, IL-10, TGFb, and Foxp3 were determined as
previously described (Gorman et al, 2007b) and normalized to
eukaryotic translation elongation factor 1a (Hamalainen et al, 2001).
Primer pairs for eukaryotic translation elongation factor 1a, IL-10,
TGFb, and Foxp3 have been described previously (Gorman et al,
2007b, 2010) and for IL-2 are 50-TTTCAATTCTGTGGCCTGCTT-30
and 50-CAGGATGGAGAATTACAGGACCT-30.
Stimulation of CD4þCD25þ cells in vitro
Purified CD4þCD25± cells were stimulated for 18 hours with
10 mgml1 plate-bound anti-CD3 mAb (17.A2; BD Biosciences,
Heidelberg, Germany) ±1mgml1 soluble anti-CD28 mAb (37.51;
BD Biosciences) or 10 mgml1 PMA (Sigma) and 400 ngml1
ionomycin (Sigma) in complete RPMI medium (Gibco, Auckland,
New Zealand) with 2mM L-glutamine, 50mM 2-ME, 5mgml1
gentamicin, and 5% normal mouse serum.
FACS analysis and antibodies
Staining of surface Ags was performed as previously described (Gorman
et al, 2007a). An IL-2 secretion assay kit (Miltenyi Biotec) was used to
determine the proportion of IL-2 secreting cells in conjunction with a
Foxp3 intracellular staining kit (eBiosciences, San Diego, CA). A
method previously described (Meindl et al, 2005) was used to
determine intracellular VDR expression by CD4þCD25± cells using
a biotinylated anti-VDR antibody (Neomarkers, Fremont, CA) or rat
IgG2b isotype (BD Biosciences) with PE-Cy5-SA (BD Biosciences). Data
were analyzed using FlowJo software (Tree Star, Ashland, OR).
In vitro vitamin D treatment
Purified CD4þCD25± cells from the lymph nodes of naive BALB/c
mice were incubated in round-bottomed 96-well trays at 105 cells
per 200ml in complete RPMI with 10% fetal calf serum for 4, 24, or
96 hours with 10 nM 1,25(OH)2D3 (dissolved in ethanol). In
some treatments, cells were supplemented with 6 or 15 ngml1
rIL-2 (BD Biosciences). After 72 hours culture, methyl-[H3]-thymi-
dine (0.25mCi; 10 ml per well; Amersham, Pharmacia Biotech,
Piscataway, NJ) was added to cultures for the final 24 hours.
CHS responses
At 4 or 24 hours after in vitro treatment, CD4þCD25þ cells were
washed three times with 0.9% saline and then 2.5 105 cells
adoptively transferred through the tail vein into naive BALB/c mice
(five mice per group). At 24 hours after adoptive transfer, a CHS
assay was performed using 2,4-dinitrofluorobenzene (Sigma) as
previously described (Gorman et al, 2007a; Hart et al, 1998).
Statistical analyses
Data were compared using the Student’s t-test on the Prism statistical
analysis programs for Macintosh (v5.0a, GraphPad Software, Inc., La
Jolla, CA). For analysis of PCR data, fold-change was transformed
by log2 and then a one-sample t-test was performed. An up- or
downregulation of a particular gene transcript was considered to be
significant with a P-valueo0.05, and where it was regulatedX2-fold.
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